🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

IAN Group leads seed round in medtech startup SVASTEK

EntrackrEntrackr · 5m ago
IAN Group leads seed round in medtech startup SVASTEK
Medial

Medtech startup SVASTEK has raised Rs 2 crore in a seed funding round led by IAN Angel Fund. The funds will be utilized to launch the ALLTIP-enabled NIV mask across India, build a distributor network for product availability, expand its clinical application team, and drive awareness through medical conferences and targeted outreach programs, SVASTEK said in a press release. Launched in 2022 by Arita Abrol, SVASTEK is a healthcare startup focused on solving challenges within respiratory and critical care through patented solutions designed for large-scale hospital use. The company aims to empower patient care by addressing critical gaps in existing medical technologies. According to the Delhi-based company, its flagship product, the ALLTIP Technology-enabled NIV mask, offers a groundbreaking solution for continuous non-invasive ventilation while allowing simultaneous nutrition delivery, improving clinical outcomes and reducing malnutrition-related risks in patients on long-term respiratory support. As per market research, the respiratory and critical care market in India is valued at Rs 48,500 crores (about $5.8 billion) and is growing at a CAGR of 8.3%. With plans to expand its product portfolio and geographical footprint, the company aims to establish itself as a global leader in respiratory care, driving innovation, affordability, and accessibility in healthcare.

Related News

Medtech startup MedVital raises Rs 8.4 Cr in pre-seed round

EntrackrEntrackr · 2m ago
Medtech startup MedVital raises Rs 8.4 Cr in pre-seed round
Medial

Medtech startup MedVital raises Rs 8.4 Cr in pre-seed round MedVital, a medtech startup focused on skin repair and wound care, has raised Rs 8.4 crore in its pre-seed round led by Nihar Parikh’s 4point0 Health Ventures. The round saw participation from founders of Tata 1mg, NephroPlus, SafeExpress, Eye Q Hospital, Hexa Health, and AstroTalk. The proceeds will be used to expand MedVital’s product portfolio, strengthen its supply chain, and broaden its distribution network to cover hospitals, clinics, and home-care settings. Co-founded by Varun Gupta and Tarun Bansal, MedVital is a full-stack platform for wound care and minimally invasive aesthetics, integrating monitoring and next-generation biomaterials. MedVital’s flagship product, NoWound, is a negative pressure wound therapy (NPWT) device designed for controlled healing of complex wounds. The device is compact, digitally enabled, and locally manufactured. The startup plans to introduce liquid chitosan-based dressings and expand into dermal and hair regeneration solutions.

PlaySuper raises $500K in seed round led by IAN Group and 100X.VC

EntrackrEntrackr · 5m ago
PlaySuper raises $500K in seed round led by IAN Group and 100X.VC
Medial

Snippets PlaySuper raises $500K in seed round led by IAN Group and 100X.VC Gaming commerce startup PlaySuper has raised $500K in its seed round led by IAN Angel Fund and 100X.VC. The round also saw participation from angel investors including Uday Sodhi, KRS Jamwal, Pratham Mittal, Rajit Bhattacharya, and Ankit Das, among others. The proceeds will be used to accelerate product development, expand market reach, and strengthen hiring. PlaySuper is set to launch its next-gen, hyper-personalized in-game store, allowing easy integration without requiring updates. The Gurugram-based brand also plans to expand into Southeast Asia (SEA) within six months, followed by MENA and LATAM. Additionally, it will bring in a Product Head and expand its B2B partnerships team to onboard more gaming studios. Founded in April 2024 by Shouradeep Chakraborty, PlaySuper enables gamers to shop inside their favorite mobile games while playing. It integrates real-world shopping experiences within mobile games. Shouradeep and Upamanyu previously co-founded LectureNotes, an edtech platform that raised $2.5 million in 2022. They bring extensive experience from the gaming, Web3, and edtech sectors. Over the next year, the company will focus on launching its in-game store, scaling its reach into new markets, and deepening its collaborations with game developers.

MiClient raises seed round from IAN Group, others

EntrackrEntrackr · 11m ago
MiClient raises seed round from IAN Group, others
Medial

MiClient, an AI-driven B2B sales enablement platform, has raised Rs 3.9 crore in its seed funding round led by IAN Group with participation from Anicut, GSF, RTAF, and Keiretsu. Vikas Kuthiala and Pratik Mathurkar from IAN led the round. The round follows an initial pre-seed investment in October 2023 from 100x.VC. The proceeds will be used to build a stronger team and expand market presence across more geographies in India. In addition to market expansion, MiClient is developing an AI-based model to create quotations and invoices in seconds, further streamlining the sales process for its users. Led by Swati Sharma, MiClient’s easy-to-use CPQ platform helps sales teams close deals three times faster, with the average deal now closing in just 10 days. Expanding further into India’s industrial hubs, MiClient is executing a feet-on-the-street go-to-market strategy. MiClient is expanding into more industrial hubs across India using a direct sales approach. With over 150 customers and over 1,500 users, the company serves SMEs, particularly in the B2B manufacturing sector, with a user-friendly platform.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 17d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.